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Informed Consent
To the Editor: In their review article (March 2 
issue),1 Grady and colleagues suggest that techno-
logical advances could help to facilitate obtaining 
informed consent without an in-person meeting 
between participants and investigators. However, 
we believe that true informed consent needs to 
go beyond symbolic measures such as clicking 
blocks electronically or supplying a signature.
Without an in-person meeting, participants 
may feel coerced into participating without the 
researcher being aware of it. In addition to se-
curing the privacy and confidentiality of partici-
pants, mutual trust and confidence must be built 
while sharing the emotions regarding fear and 
anxiety about uncertainty and unpredictability 
of the trial outcome.2,3 We believe that in-person 
discussion is an imperative step in obtaining 
informed consent in most clinical trials.
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To the Editor: The electronic tools highlighted by 
Grady et al. may help to address the challenges of 
poor comprehension of research information re-
sulting from complex and lengthy paper-based 
informed-consent forms. Such innovative strate-
gies could be of paramount importance in the con-
text of high illiteracy rates or a lack of standard-
ized writing formats for the local languages.1,2
Although we agree that electronic tools could 
improve participants’ comprehension, we are sur-
prised that the inherent challenges that are posed 
by implementing such strategies in low-resource 
countries,3 where an increasing number of clini-
cal trials are taking place, were not discussed. 
We think that poor Internet access coupled with 
few Internet-enabled smartphones, along with 
concerns that electronic tools may weaken the 
element of human interactions that form the 
basis of research ethics, need to be considered. 
We believe that the overall acceptance and suc-
cess of the electronic informed-consent tools in the 
African context will ultimately depend on a well-
balanced and tailored combination of some tra-
ditional tools, technology, and human elements.4
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The author replies: Goh and Shin highlight 
the value of in-person discussion in the informed-
consent process for most clinical trials. My col-
leagues and I agree that in-person discussions 
are the most appropriate method for informed 
consent for the majority of clinical trials. It could 
very well be difficult to assess voluntary choice 
and evaluate body language without meeting a 
potential participant, as noted in Table 1 of our 
article, but voluntariness is challenging to evalu-
ate in any case.1 Nonetheless, as emphasized, the 
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appropriateness of particular informed-consent 
strategies crucially depends on context, which 
includes at least the research question, the type 
of interventions and data being collected, the 
populations to be included, where they live, their 
literacy level, and their access to and familiarity 
with technology. For example, some large prag-
matic trials currently enroll thousands of persons 
from various locations without the need to visit a 
health care facility or meet in person with an 
investigator. For certain pragmatic trials, espe-
cially those with little to no added research risk, 
a requirement for in-person informed consent is 
unnecessary as long as participants have the in-
formation they need to make decisions about 
participation and can choose whether or not to 
participate.2 Similarly, informed consent for sec-
ondary research with data and biospecimens might 
appropriately be remote, regardless of whether it 
is broad or study-specific.
Afolabi and García-Basteiro mention that the 
choice of technological approaches to informed 
consent for a given trial has to account for the 
availability of, and access to, the planned tech-
nologies. Clearly, such availability and access 
can vary dramatically, and not just between low-
resource and high-resource countries. Disparities 
in familiarity and comfort with technology should 
also be considered. My colleagues and I tried to 
capture these ideas briefly by emphasizing that 
context always matters and by recognizing that 
“informed consent will require the creative use 
of technologies that are simple, easy to use, and 
in widespread and common use.” Widespread and 
common use was intended to refer to partici-
pants who are likely to be enrolled in the trial, 
regardless of where they live. Respectful and 
effective informed-consent strategies depend on 
tailoring methods appropriate for the context and 
potential participants.3
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